预估葡萄糖处理率与肝脏脂肪变性和肝纤维化的相关性分析

Associations of estimated glucose disposal rate with liver steatosis and fibrosis

  • 摘要:
    目的 探讨预估葡萄糖处理率(eGDR)与代谢功能障碍相关肝脏脂肪变性和肝纤维化的相关性, 并分析这种关联性在不同人群特征中的差异。
    方法 纳入2017—2020年美国国家健康与营养调查(NHANES)数据库中10 549例参与振动控制瞬时弹性成像技术(VCTE)检查的参与者为研究对象。通过腰围、高血压和糖化血红蛋白(HbA1c)计算eGDR。以受控衰减参数(CAP)≥248 dB/m作为肝脏脂肪变性诊断标准,以肝脏硬度(LSM)≥8.2 kPa作为肝纤维化的判定标准。采用多因素Logistic回归分析评估eGDR与肝脏脂肪变性和肝纤维化的关系,并进行亚组分析和交互作用检验。
    结果 调整混杂因素后, eGDR水平与肝脏脂肪变性和肝纤维化风险均呈显著负相关。将研究对象按eGDR水平三分位数(Q1Q2Q3)分为Q1组、Q2组和Q3组。与Q1组相比, Q2组和Q3组肝脏脂肪变性的风险比分别为0.485(95% CI: 0.394~0.597)和0.286(95% CI: 0.239~0.343), 差异均有统计学意义(P < 0.001);肝纤维化风险比分别为0.457(95% CI: 0.363~0.576)和0.162(95% CI: 0.100~0.263), 差异均有统计学意义(P < 0.001)。亚组分析结果显示, eGDR与肝脏脂肪变性的负相关性在不同年龄和吸烟状态人群中存在差异,交互作用检验差异有统计学意义(P交互 < 0.001);eGDR与肝纤维化的负相关性在不同体力活动人群中的交互作用检验中差异有统计学意义(P交互 < 0.001)。eGDR水平与肝脏脂肪变性和肝纤维化的相关性保持稳定(P交互>0.05)。
    结论 eGDR水平与肝脏脂肪变性和肝纤维化风险密切相关,可作为评估肝脏代谢异常的有效指标。这一发现为肝脏脂肪变性和肝纤维化早期筛查、风险分层和预后评估提供了新思路。

     

    Abstract:
    Objective To investigate the association of estimated glucose disposal rate (eGDR) with metabolic dysfunction-associated liver steatosis and fibrosis, and to analyze the difference of the association in different population.
    Methods A total of 10, 549 participants from 2017 to 2020 in National Health and Nutrition Examination Survey (NHANES) database who underwent vibration-controlled transient elastography (VCTE) were included. eGDR was calculated based on waist circumference, hypertension, and glycated hemoglobin (HbA1c). The controlled attenuation parameter (CAP) ≥ 248 dB/m was used as diagnostic criterion for liver steatosis, and liver stiffness measurement (LSM) ≥ 8.2 kPa was used as criterion for liver fibrosis. Multivariable Logistic regression analysis was conducted to assess the relationship between eGDR and liver steatosis and fibrosis, with subgroup analysis and interaction tests performed.
    Results After adjusting for confounding factors, eGDR level was significantly negatively associated with the risks of both liver steatosis and fibrosis. The participants were divided into tertiles based on eGDR levels (Q1, Q2, Q3). Compared with the Q1 group, the risk ratios for liver steatosis in the Q2 and Q3 groups were 0.485 (95%CI, 0.394 to 0.597) and 0.286 (95%CI, 0.239 to 0.343), respectively(P < 0.001); the risk ratios for liver fibrosis were 0.457 (95%CI, 0.363 to 0.576) and 0.162 (95%CI, 0.100 to 0.263), respectively (P < 0.001). Subgroup analysis showed that the negative association between eGDR and liver steatosis differed among populations of different ages and smoking statuses, with statistically significant differences in interaction tests (P for interaction < 0.001); similarly, the negative association between eGDR and liver fibrosis differed among populations with different levels of physical activity, with statistically significant differences in interaction tests (P for interaction < 0.001). The associations of eGDR levels with liver steatosis and fibrosis remained stable (P for interaction>0.05).
    Conclusion eGDR levels are closely associated with the risks of liver steatosis and fibrosis and can serve as an effective indicator for assessing liver metabolic abnormalities. This finding provides new insights into early screening, risk stratification, and prognosis assessment for liver steatosis and fibrosis.

     

/

返回文章
返回